Genital condylomata in a patient receiving infliximab for Crohn’s disease
- Correspondence to: Dr R Alcolado Royal Glamorgan Hospital, Llantrisant CF72 8XR, Wales, UK;
- Received 13 May 2003
- Accepted 4 August 2003
Infliximab is a monoclonal antibody against tumour necrosis factor-alpha. Recent studies have shown that it is effective in treating patients with refractory Crohn’s disease and in those with Crohn’s fistulae. Though this drug is found to be safe in clinical trials, sporadic reports of serious complications have been recorded in the literature. The case of a patient who developed profuse genital warts after infliximab treatment is reported. The literature is reviewed and information is presented on side effects and complications as a result of infliximab therapy.